Curriculum Vitae - Vaskar Saha

NAME: **Vaskar Saha**
Manchester M20 4BX

WEBSITE: http://www.cancer.manchester.ac.uk/research/paediatric/
http://www.tmckolkata.com/tmc/ttcrc.php

QUALIFICATIONS:

MBBS, DCH, MD (PAEDS), FRCPCH, PhD, FRCPATH

APPOINTMENTS: (from Sep 2006)

Director, Tata Translational Cancer Research Centre, Kolkata

Senor Consultant in Paediatric Oncology, Tata Medical Center, Kolkata

Centre Lead for Paediatric, Teenage and Young adult Cancer, University of Manchester (2013 – 2014)

Research Group Lead for Cancer Studies, University of Manchester (2006 – 2013)

Professor of Paediatric Oncology, University of Manchester

Head, Cancer Research UK Children's Cancer Group

Honorary Consultant in Paediatric Oncology Central Manchester and Manchester Children's University Hospitals NHS Trust

Honorary Consultant, Christie Hospital NHS Trust, Manchester

PUBLICATIONS 2005-

Publications with regards to Leukaemia

1. Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, **Saha V**, Shankar A.. Adenovirus infection following paediatric bone marrow transplantation: Is treatment always necessary? *Clin Infect Dis* 2005; 40:1244-1249.

2. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, **Saha V**. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 Trial. *Br J Haematol* 2005; 129:35-44.

3. van Delft FW, Belloti T, Luo Z, Jones LK, Patel N, Yiannikouris O, Hill AS, Hubank M, Kemspki H, Fletcher D, Chaplin T, Foot N, Young BD, Hann I, Gammerman A, **Saha V**. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia *Br J Haemato*l 2005;130:26-35.

4. Bury J, Hurt C, Roy A, Cheesman L, Bradburn M, Cross S, Fox J, **Saha V**. LISA - a web-based trial management and decision support system for childhood acute lymphoblastic leukaemia *Br J Haematol* 2005;129: 746-754.

5. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, **Saha V**. Outcome of first relapse in childhood acute lymphoblastic leukaemia - experiences from the UKALL R2 protocol. *Br J Haematol* 2005;130:60-75.

6. Jones LK, **Saha V**. Philadelphia positive acute lymphoblastic leukaemia of childhood. *Br J Haematol* 2005; 130:489-500.

7. Belloti T, Luo Z, Gammerman A, van Delft F, **Saha V**. Qualified predictions for microarray and proteomics pattern diagnostics with confidence machines. *Int J Neural Sys* 2005; 15:247-268.

8. Strefford JC, van Delft FW, Robinson HM, Worley H, Selzer R, Young BD, **Saha V**, Harrison C. RUNX1 amplification in childhood acute lymphoblastic leukaemia exhibits consistent genomic amplification, chromosome instability and a distinct gene expression signature. *Proc Natl Acad Sci U S A* 2006; 103:8167-8172.

9. Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, **Saha V,** Moorman AV, Harrison CJ. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. *Oncogene*. 2007 Jan 22.

10. **Saha V.** Simplifying treatment for children with ALL. *The Lancet*. 2007 Jan 13;369(9556):82-3.

11. Patel N, Krishnan S, Offman MN, Krol M, Moss CX, Leighton C, van Delft FW, Holland M, Liu J, Alexander S, Dempsey C, Ariffin H, Essink M, Eden TO, Watts C, Bates PA, **Saha V**. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. *The Journal of Clinical Investigation*. 2009 Jul;119(7):1964-73.

12. Krishnan S, Wade R, Moorman AV, Mitchell C, Kinsey SE, Eden TO, Parker C, Vora A, Richards S, **Saha V**. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia. 2010 Feb;24(2):450-9.

13. **Saha V**, Shanson E, Shankar A, Samuel D, Millar M. Hospital ventilation, heat and humidity: risk of fungal and other infections. J Hosp Infect. 2010 May;75(1):74-5.

14. Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, **Saha V**, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, PUI CH, Grazia Valsecchi M. Clinical Outcome of 610 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia treated Between 1995 and 2005. Journal of Clinical Oncology. 2010 Nov 1;28(31):4755-61.

15. Offman MN, Krol M, Patel N, Krishnan S, Liu J, **Saha V**, Bates PA. Rational engineering of L-Asparaginase reveals importance of dual activity for cancer cell toxicity. Blood. 2010 Nov 24.

16. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Revesz T, Darbyshire P, Love S, **Saha V**. Mitoxantrone Improves Outcome of Children with First Relapse of Acute Lymphoblastic Leukaemia - Results of the Randomised ALL R3 Trial. *The Lancet*. 2010 Dec 11;376(9757):2009-2017.

17. van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, Zuna J, Eckert C, **Saha V**, Kearney L, Ford A, Greaves M. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukaemia. *Blood*. 2011 Apr 11.

18. Holland M, Castro FV, Alexander S, Smith D, Liu J, Walker M, Bitton D, Mulryan K, Ashton G, Blaylock M, Bagley S, Connolly Y, Bridgemen J, Miller C, Krishnan S, Dempsey C, Masurekar A, Stern P, Whetton A, **Saha V**.RAC2, AEP and ICAM1 expression are associated with CNS disease in a mouse model of Pre-B childhood acute lymphoblastic leukaemia. *Blood*. 2011 May 23. Prepublished online.

19. van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, Zuna J, Eckert C, **Saha V**, Kearney L, Ford A, Greaves M. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. *Blood*. 2011 Jun 9;117(23):6247-54.

20. Offman MN, Krol M, Patel N, Krishnan S, Liu J, **Saha V**, Bates PA. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. *Blood*. 2011 Feb 3;117(5):1614-21.

21. Schrappe M, Hunger SP, Pui CH, **Saha V**, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. *New Engl J Med*. 2012 Apr 12;366(15):1371-81

22. Castro FV, McGinn OJ, Krishnan S, Marinov G, Li J, Rutkowski AJ, Elkord E, Burt DJ, Holland M, Vaghjiani R, Gallego A, **Saha V**, Stern PL. 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. *Leukemia*. 2012 Jan 23.

23. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, **Saha V**, Valsecchi MG. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. *The Lancet Oncology*. 2012 August 13.

24. Liu J, Masurekar A, Holland M, Johnson S, Krishnan S, Alexander S, Parker C, Dempsey C, **Saha V**. Abstract 1506: Bone marrow microenvironment mediated redox adaptation confers drug resistance in acute lymphoblastic leukaemia. *AACR* 2012.

25. Chen DW, **Saha V**, Liu JZ, Schwartz JM, Krstic-Demonacos M. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. *Oncogene*. 2013 Jun 20;32(25):3039-48.
26. van der Veer, A., Zaliova, M., Mottadelli, F., De Lorenzo, P., Te Kronnie, G., Harrison, C. J., Cave, H., Trka, J., **Saha, V.**, Schrappe, M., Pieters, R., Biondi, A., Valsecchi, M. G., Stanulla, M., den Boer, M. L. & Cazzaniga, G. (2013). IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. *Blood*.
27. Stevens A, Hanson D, de Leonibus C, Whatmore A, Donn R, White DJ, Liu J, van den Heuvel-Eibrink MM, **Saha V**, Clayton PE, Meyer S. (2014). EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age. *Blood Cancer Journal.*
28. Masurekar A, Fong C, Hussein A, Revesz T, Hoogerbrugge PM, Love S, Ciria C, Parker C, Krishnan S, **Saha V**. The optimal use of PEG-Asparaginase in relapsed ALL-lessons from the ALLR3 Clinical Trial. *Blood cancer journal*. 2014;4:e203.
29. Masurekar A, Parker C, Shanyinde M, Moorman A, Hancock J, Sutton R, Ancliff P, Morgan M, Goulden N, Fraser C, Hoogerbrugge P, Revesz T, Darbyshire P, Krishnan S, Love S, Saha V. (2014). Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. *PLOS One.* 2014, 9 (10)

Books

1. Attard-Montalto S, **Saha V** (editors). Textbook of Paediatrics. *Churchill Livingstone* Second Edition (2005)

2. Shankar A, **Saha V**. Non Hodgkin's Lymphomas of childhood. In: Lymphomas, 2nd edition. Editors: Canellos GP, Lister TA, Young BD. Pub WB Saunders (2006)

3. Kearns P, **Saha V**. New agents for the treatment of acute lymphoblastic leukaemia. New York: Springer 2011